Company news: Gilead, Pfizer and Wolters Kluwer

Share this article:

Two potential blockbusters in the pharma pipeline took another step toward reaching market. US regulatory authorities assigned August 2012 PDUFA dates for Gilead Sciences' Quad pill and for Pfizer's tofacitinib. Quad is a single-tablet HIV regimen containing four agents, while tofacitinib is set to become the first oral rheumatoid arthritis drug to enter the injectable RA space. NDAs for both drugs had been submitted earlier this year.

Wolters Kluwer said it completed the sale of its pharma-related marketing & publishing services business to Springer Science+Business Media. The sale, announced in November, is part of Wolters Kluwer's strategy to focus on core health markets through its Wolters Kluwer Health & Pharma Solutions division.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.